CSI Market
Sign In | Register

Aslan Pharmaceuticals Limited (ASLN) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access ASLN Annual Income Statement →
Income statement data covering Aslan Pharmaceuticals Limited–Dec 31 2022 offers a view into how Dec 31 2023's operating results have moved alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
Q4 2023 		0 0 0 (Dec 31 2022)
Revenues
Revenue From Contracts With Customers12.00
Total Revenue12.00
Costs & Expenses
Gross Profit12.00
Selling, Administration, Marketing13.24
Research and Development Expense42.50
OtherOperating Income Expense0.00
Total operating costs including COS55.74
Operating income / -loss-43.74
Net Interest Expense / -Income0.00
Other loss / -income-4.32
Total costs & expenses56.09
Income & Taxes
Income / -loss before income taxes-44.09
Income taxes expenses / -benefit0.13
Income after income taxes-44.22
Income / -loss from continuing operations-44.22
Net income / -loss-44.22
Income / -loss to shareholder-44.22
EBIT0.00
EBITD0.00
EBITDA0.00
Earnings Per Share
Basic EPS (excl. extra items)-0.11
Basic Net EPS-0.11
Basic shares outstanding (Mill. of Units)402.00
Diluted Net EPS-0.11
Diluted average shares (Mill. of Units)402.00
4 historic quarters locked

Sign in to unlock the full Aslan Pharmaceuticals Limited income statement history.

Sign In Create Free Account

About ASLN Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.